Cancer, Hematologic disease, Immune disorders
Conditions
Interventions
Patients undergo controlled ovarian stimulation and in vitro fertilization (IVF) for fertility preservation before or in the course of treatment for primary disease. Combined therapy: FSH/hMG in
Sponsors
Keio University
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1) Cancer, hematological disease, or immune disorders. 2) Physicians referral for fertility preservation. 3) The patients who are expected long-term survival. 4) The patients who have the ability to provide written informed consent.
Exclusion criteria
Exclusion criteria: 1. Freezing 1) The patients who cannot realize or obtain informed consent. 2) The patients judged to be inappropriate for the study by the physicians. 3) The case to delay treatments because of fertility preservation. 2. Fertilization, Embryo Transfer 1) Unmarried patients. 2) The patients who are more than 50 years old. 3) The patients undergoing hysterectomies. 4) The patients whose cancers, hematological diseases, or immune disorders have progressed at the time of embryo transfer.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Survival rate of oocytes and embryos after freezing and thawing | — |
Secondary
| Measure | Time frame |
|---|---|
| Total dose of gonadotropins, Oocytes retrieval number, Total number of mature oocytes, Fertilization rate, Blastocyst development rate, The ratio of embryos available for transfer per oocyte pick up, Implantation rate per embryo transfer, Liver birth rate per oocyte pick-up | — |
Countries
Japan
Contacts
Public ContactMitsutoshi Yamada
Keio University School of Medicine Department of Obstetrics and Gynecology
Outcome results
None listed